Cases in the Clinic: Aligning Your Practice to the Evolution of HR-Positive Metastatic Breast Cancer скачать в хорошем качестве

Cases in the Clinic: Aligning Your Practice to the Evolution of HR-Positive Metastatic Breast Cancer

Join us for this live event! As a nurse, you are on the front lines, providing essential education and compassionate care for your patients. This session is designed to empower you with the knowledge needed to support patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC). We'll explore the mechanism of endocrine resistance and show how new, targeted therapies can improve quality of life and improve treatment outcomes. Through interactive case studies, you'll learn to recognize and manage the side effects of novel agents, ensuring your patients remain on treatment longer and feel better. We'll also cover the importance of genomic testing and how it helps create truly personalized care plans. You'll leave with practical skills and the confidence to advocate for your patients to discuss cutting-edge therapies with them and the care team. TARGET AUDIENCE This educational activity is intended for an audience of physician assistants, nurse practitioners, nurses, pharmacists, and other members of the breast cancer care team in the United States. GOAL STATEMENT The goal of this activity is for learners to be better able to enhance the quality of life (QOL) of patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC) by improving the knowledge, competence, and confidence of advanced practice providers regarding biomarker-driven therapies. LEARNING OBJECTIVES Upon completion of this activity, learners will: Have increased knowledge regarding the Development of endocrine resistance in patients with HR-positive, HER2-negative MBC Have greater competence related to Tailoring treatment selection to the presence of actionable biomarkers for patients with HR-positive, HER2-negative MBC Managing adverse events (AEs) related to novel targeted therapies used to manage patients with HR-positive, HER2-negative MBC Demonstrate greater confidence in their ability to Introduce biomarker-driven care into treatment planning for patients with HR-positive, HER2-negative MBC ACCREDITATION STATEMENT In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. accreditation logo medscape logo For Physicians Medscape, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For Nurses Awarded 1.0 contact hour(s) of nursing continuing professional development for RNs and APNs. For Pharmacists Medscape designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) (Universal Activity Number: JA0007105-0000-25-338-L01-P)